Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Rasagiline in Restless Legs Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women at least 18 years of age, capable of providing informed consent~* Diagnosed with idiopathic RLS, defined as meeting the International RLS Study Group diagnostic criteria without evidence for secondary causes of RLS~* Moderate or severe symptoms, defined as a score of 15 or greater on the International RLS Study Group Rating Scale (IRLS)~* Not currently receiving treatment for RLS. A 30-day washout period will be required for participants on dopamine agonists or other therapies. Stable doses of iron supplementation will be allowed~* On a stable dose of the following antidepressants, for at least 30 days prior to baseline visit:~  * Amitriptyline, up to 50mg/day~ * Trazodone, up to 100mg/day~ * Citalopram, up to 20mg/day~ * Escitalopram, up to 10mg/day~ * Paroxetine, up to 30mg/day~ * Sertraline, up to 100mg/day~* Female subjects must not be of childbearing potential or must agree to use of contraception for duration of study~Exclusion Criteria:~* Signs consistent with a secondary cause of RLS:~* History of initial unresponsiveness to dopaminergic RLS treatment despite adequate dose of initial therapy~* Use of another MAO inhibitor within 30 days of baseline visit~* Allergy or adverse reaction to rasagiline~* Prior adverse reaction to tyramine-containing foods~* Use of meperidine or other opiates within 30 days of the baseline visit~* Use of benzodiazepines within 30 days of the baseline visit~* Use of antidepressants, including TCAs, SSRIs, and SNRIs, except for those permitted as listed above~* Use of other drugs or supplements contraindicated with rasagiline, including St. John's wort, mirtazapine, cyclobenzaprine, dextromethorphan, cold products that contain ephedrine, pseudoephedrine~* Scheduled to undergo elective surgery during the course of the study~* Active medical or psychiatric illness that requires changes to treatment during the course of the study or jeopardize the subject's ability to remain in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rasagiline (Type: ACTIVE_COMPARATOR): None
- placebo (sugar pill) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).